Skip to NavigationSkip to content


Five more biosimilar-free years for AbbVie’s megablockbuster

Humira is the key drug for AbbVie, and one the company hopes it will be able to push into the $20 billion region per year region before competition arrives. After a financial deal was agreed with Amgen, it looks like the drug should have the immediate biosimilar threat removed from its path running up to the beginning of 2023.

Roche and AbbVie's leukaemia combo smashes Phase 3 endpoint

Venclexta/Venclyxto (venetoclax), Roche and AbbVie’s oral B-cell lymphoma-2 (BCL-2) inhibitor, successfully met its primary endpoint in Phase 3 trials, providing prolonged, progression-free survival in chronic lymphocytic leukaemia (CLL) when administered with Rituxan (rituximab).

Sandoz psoriasis biosimilar tops reference product Humira in latest Phase 3 data

Sandoz, the biologics and generics division of Novartis, has unveiled new Phase 3 data confirming the efficacy and safety profile of its biosimilar adalimumab is on par with its reference product, Abbvie’s Humira – currently the world’s best-selling drug.

Questions raised after two deaths in AbbVie arthritis study

AbbVie’s rheumatoid arthritis drug, upadacitinib, is the company’s big plan to manage the inevitable loss of sales from Humira, as biosimilars begin to take chunks out of its market space. Only last month, the FDA approved Boehringer Ingelheim’s Cyltezo as a biosimilar to the drug – joining Amgen’s Amjevita.

New potential blockbuster RA treatment enters European market

The world’s biggest selling drug, AbbVie’s Humira with $16 billion in sales last year, has a new rival in the European market, as Sanofi and Regeneron’s Kevzara (sarilumab) has gained marketing authorisation from the European Commission in rheumatoid arthritis (RA). The drug is already predicted to take a $1 billion and above slice of the market place, after preceding approvals in the US and Canada.

AbbVie loses $15 million Depakote birth-defect case

Court cases for the anti-seizure medicine Depakote continue to rumble on for AbbVie, with the latest case finding AbbVie liable to pay $15 million in damages for the care of a boy born with birth defects. There are a further 700 cases pending across the US regarding the drug, with this case taking place in a federal court in Illinois.

AbbVie posts promising data on RA drug

AbbVie posted results on upadacitinib, the latest drug in its pipeline for rheumatoid arthritis (RA) and the results have given the company a huge boost by managing to hit all endpoints. Alongside the positive results against placebo, the drug was also able to display a consistent safety profile from previous Phase 2 trials.

Abbvie names new General Managers for UK and France

Published on: 02/06/17

Abbvie has announced a double appointment across its UK and French operations, naming Jérôme Bouyer as its UK General Manager, UK, and Pierre-Claude Fumoleau succeeds him as General Manager, France.

AbbVie suffers knock to Humira patent

Humira is the largest selling pharmaceutical drug in the world. The treatment for rheumatoid arthritis brought in over $16 billion for AbbVie in 2016 alone so it should come as no surprise that there are a few companies looking to get their biosimilars to market to attain a slice of the profit.

The problem facing any company trying to do this is the wall of patents that AbbVie has built around its product to protect it from this eventuality. However, it has suffered a minor blow as one brick has been taken out of this protection with the loss of the ‘135 patent.

AbbVie’s experimental cancer drug hits wall in clinical study

AbbVie have released that two Phase 3 trials of its experimental cancer drug, veliparib, missed both of their primary endpoints. Veliparib is part of a new wave of drugs called PARP inhibitors and AbbVie were investigating whether it could improve overall survival in cancer patients.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches